KT-621
Small Molecule Target: STAT6
Kymera Therapeutics, Inc.
Most recent annual filing: 2026-02-26
Pipeline (5 active programs)
KT-579
Small Molecule Target: IRF5
- Undisclosed indication
KT-485
SAR447971 Small Molecule Target: IRAK4
- Undisclosed indication
- Undisclosed indication
Technology platforms
CDK2 Molecular Glue Degrader Program · Gilead Sciences
Discovery and preclinical research collaboration with Gilead Sciences to develop novel molecular glue degraders directed against cyclin-dependent kinase 2 (CDK2); Gilead holds exclusive option to license and commercialize globally
Targets: CDK2
Discontinued (1)
- KT-474 — undisclosed · Sanofi stopped development of KT-474 following decision to advance KT-485/SAR447971
Biotech Distilled coverage (2)
- 2026-04-13 UPDATE: Kymera Therapeutics (KYMR) - Cashes a $45M Lottery Ticket and Greases the Regulatory Skids 🔒 Paid
- 2026-04-09 Kymera Therapeutics (KYMR) - Scientific Deep Dive on KT-621 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.